drugset / Trial / NCT04366713
A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib
NaSingle-groupOpen-labelOther
Summary
This study will investigate colon pathology in patients with HER2-positive breast cancer treated with neratinib. Colonoscopy will be performed after eligibility has been confirmed, prior to administration of the first dose of neratinib, and after 28 days of neratinib treatment.
Timeline
- Start
- 2020-06-30
- Primary completion
- 2021-12-28
- Completion
- 2021-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neratinib | Small molecule | 240 mg | Oral |
| Background | Capecitabine | Small molecule | 750 mg/m2 | Oral |
| Background | Loperamide | Small molecule | — | Oral |